Concepedia

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov,

The Lancet Oncology · 2019 · 796 citations · 19 references

DOI

Concepts

References

19

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje, Jesús G. Berdeja, Yi Lin et al. · New England Journal of Medicine · 2019 · 1.7K citations · Full text

, , +17

BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

Brian P. O’Connor, Vanitha S. Raman, Loren D. Erickson et al. · The Journal of Experimental Medicine · 2004 · 1.1K citations · Full text

, , +14

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer N. Brudno, Irina Marić, Steven D. Hartman et al. · Journal of Clinical Oncology · 2018 · 791 citations · Full text

, , +15

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer et al. · Journal of Clinical Investigation · 2019 · 790 citations · Full text

, , +17

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

, , +15